Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Mar 2025

Geynisman Daniel M, Abbosh Philip H, Ross Eric, Zibelman Matthew R, Ghatalia Pooja, Anari Fern, Mark James R, Stamatakis Lambros, Hoffman-Censits Jean H, Viterbo Rosalia, Greenberg Richard E, Churilla Thomas M, Horwitz Eric M, Hallman Mark A, Smaldone Marc C, Uzzo Robert, Chen David Y T, Kutikov Alexander, Plimack Elizabeth R

Abstract excerpt

PURPOSE: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic downstaging after NAC. We hypothesized that a combination of biomarker selection and clinical staging would identify patients for cystectomy-sparing active surveillance (AS). PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Doxorubicin

Share to Methotrexate

Share to Neoadjuvant Therapy

Share to Neoplasm Invasiveness

Share to Urinary Bladder Neoplasms

Share to Vinblastine

Source

Open in PubMed Open full text

Identifiers

PMID: 39680823
DOI: 10.1200/JCO-24-01214
PMCID: PMC11908952

Genes

ATM
ERCC2
FANCC
RB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).PMID 39680823Read ↗

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Semantic proximity Read ↗

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.Semantic proximity Read ↗

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.Semantic proximity Read ↗

Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSemantic proximity Read ↗

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity Read ↗

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesSemantic proximity Read ↗

Subtype-specific benefit of adjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer with histologic variants: a four-endpoint, subtype-stratified analysisSemantic proximity Read ↗

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerSemantic proximity Read ↗

Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Semantic proximity Read ↗

Modeling adaptive therapy in non-muscle invasive bladder cancerSemantic proximity Read ↗

Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentSemantic proximity Read ↗

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.